Live Breaking News & Updates on Sv Health Managers International Biotechnology

Home / Analysis / Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
Schroder Global Healthcare and Axa Framlinton Health Care have returned 519% and 289% over the past decade
The biotech and healthcare sectors have flourished during the pandemic as companies raced to develop a Covid-19 vaccine. Those already invested have reaped the rewards, but what next? Is it time to reconsider this exposure or is there more to come?
Data from Grand View Research forecasts the biotech market to grow from $752.88bn in 2020 to $2.44trn by 2028. Similarly, genomics is expected to reach $62.9bn by 2028 driven by healthcare innovation and tailoring care to an individual patient, while providing more data on diseases and human genetics. ....

Ailsa Craig , South Ayrshire , United Kingdom , James Yardley , Jenny Turton , Paul Stannard , David Pinniger , John Bowler , Bb Healthcare , Downing Four , Biotech Growth , View Research , Axa Framlington Health Care , Vector Innovation Fund , Worldwide Healthcare , Sv Health Managers International Biotechnology , International Biotechnology , Grand View Research , Vector Innovation , Schroder Global Healthcare , Biotech Growth Trust , Worldwide Healthcare Trust , Frostrow Capital , Managers International Biotechnology Trust , Impact Healthcare Reit , Laith Khalaf ,